TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Kappa Bioscience AS
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
442,230
|
321,976
|
308,808 |
| Financial expenses |
22,548
|
25,792
|
23,517 |
| Earnings before taxes |
164,315
|
111,256
|
71,151 |
| Total assets |
690,106
|
566,907
|
497,911 |
| Current assets |
273,353
|
208,815
|
227,038 |
| Current liabilities |
233,438
|
86,123
|
153,980 |
| Equity capital |
287,186
|
294,872
|
268,611 |
| - share capital |
1,475
|
1,501
|
1,608 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
41.6%
|
52.0%
|
53.9% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
37.2%
|
34.6%
|
23.0% |
| Return on assets (ROA) |
27.1%
|
24.2%
|
19.0% |
| Current ratio |
117.1%
|
242.5%
|
147.4% |
| Return on equity (ROE) |
57.2%
|
37.7%
|
26.5% |
| Change turnover |
125,957
|
33,629
|
63,467 |
| Change turnover % |
40%
|
12%
|
26% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.